[{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ Orbital","highestDevelopmentStatusID":"1","companyTruncated":"Orbital Therapeutics \/ Orbital"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Orbital Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"RNA-based therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbital Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Orbital Therapeutics \/ ARCH Venture Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Orbital Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The financing will be used to support the advancement of an Industry-leading, comprehensive platform of RNA technologies and a first-in-class portfolio of programmable RNA-based therapies.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 26, 2023

                          Lead Product(s) : RNA-based therapy

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : ARCH Venture Partners

                          Deal Size : $270.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 07, 2022

                          Lead Product(s) : RNA-based Medicine

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Recipient : Beam Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 07, 2022

                          Lead Product(s) : RNA-based Vaccine

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Beam Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank